AMAG Pharmaceuticals, Inc. (AMAG) Upgraded by BidaskClub to “Buy”
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) was upgraded by equities research analysts at BidaskClub from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, July 6th.
AMAG has been the topic of a number of other reports. Barclays PLC reissued a “hold” rating and set a $25.00 price target on shares of AMAG Pharmaceuticals in a report on Friday, May 5th. TheStreet cut AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, May 5th. Jefferies Group LLC set a $40.00 target price on AMAG Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, April 20th. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $23.00 target price on shares of AMAG Pharmaceuticals in a report on Monday, June 26th. Finally, ValuEngine cut AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have assigned a buy rating to the company’s stock. AMAG Pharmaceuticals has an average rating of “Hold” and a consensus target price of $28.09.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded up 6.63% during mid-day trading on Thursday, hitting $20.10. The stock had a trading volume of 958,235 shares. The stock’s 50-day moving average is $18.77 and its 200-day moving average is $21.08. The firm’s market capitalization is $704.40 million. AMAG Pharmaceuticals has a 1-year low of $16.00 and a 1-year high of $36.83.
AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.18. The business had revenue of $158.39 million for the quarter, compared to analysts’ expectations of $158.83 million. AMAG Pharmaceuticals had a positive return on equity of 1.69% and a negative net margin of 5.61%. The business’s quarterly revenue was up 24.3% on a year-over-year basis. During the same period last year, the firm earned $1.45 earnings per share. Equities analysts expect that AMAG Pharmaceuticals will post $5.40 earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: This piece of content was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/04/amag-pharmaceuticals-inc-amag-rating-increased-to-buy-at-bidaskclub-updated-updated-updated.html.
In other AMAG Pharmaceuticals news, SVP Julie Krop sold 4,938 shares of the business’s stock in a transaction that occurred on Thursday, July 13th. The stock was sold at an average price of $20.00, for a total transaction of $98,760.00. Following the completion of the transaction, the senior vice president now owns 28,336 shares in the company, valued at $566,720. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 3.80% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can raised its stake in shares of AMAG Pharmaceuticals by 4,071.4% in the first quarter. Bank of Montreal Can now owns 66,492 shares of the specialty pharmaceutical company’s stock worth $1,500,000 after buying an additional 64,898 shares during the last quarter. Creative Planning raised its stake in shares of AMAG Pharmaceuticals by 768.4% in the first quarter. Creative Planning now owns 13,895 shares of the specialty pharmaceutical company’s stock worth $313,000 after buying an additional 12,295 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of AMAG Pharmaceuticals by 9.5% in the fourth quarter. Teachers Advisors LLC now owns 59,891 shares of the specialty pharmaceutical company’s stock worth $2,084,000 after buying an additional 5,216 shares during the last quarter. Norges Bank purchased a new stake in shares of AMAG Pharmaceuticals during the fourth quarter worth about $19,914,000. Finally, Thrivent Financial for Lutherans raised its stake in shares of AMAG Pharmaceuticals by 5.8% in the fourth quarter. Thrivent Financial for Lutherans now owns 18,380 shares of the specialty pharmaceutical company’s stock worth $640,000 after buying an additional 1,000 shares during the last quarter.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Stock Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.